These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9788602)

  • 1. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules.
    Zajac P; Schütz A; Oertli D; Noppen C; Schaefer C; Heberer M; Spagnoli GC; Marti WR
    Cancer Res; 1998 Oct; 58(20):4567-71. PubMed ID: 9788602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
    Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
    Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope.
    Zajac P; Oertli D; Spagnoli GC; Noppen C; Schaefer C; Heberer M; Marti WR
    Int J Cancer; 1997 May; 71(3):491-6. PubMed ID: 9139889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
    Fenton RG; Turcovski-Corrales SM; Taub DD
    J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
    Hodge JW; McLaughlin JP; Abrams SI; Shupert WL; Schlom J; Kantor JA
    Cancer Res; 1995 Aug; 55(16):3598-603. PubMed ID: 7543017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonreplicating recombinant vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitro.
    Marti WR; Zajac P; Spagnoli G; Heberer M; Oertli D
    Cell Immunol; 1997 Aug; 179(2):146-52. PubMed ID: 9268498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo.
    Sigal LJ; Reiser H; Rock KL
    J Immunol; 1998 Sep; 161(6):2740-5. PubMed ID: 9743331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
    Hodge JW; Abrams S; Schlom J; Kantor JA
    Cancer Res; 1994 Nov; 54(21):5552-5. PubMed ID: 7522961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
    Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY
    Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro.
    Schumacher R; Amacker M; Neuhaus D; Rosenthal R; Groeper C; Heberer M; Spagnoli GC; Zurbriggen R; Adamina M
    Vaccine; 2005 Dec; 23(48-49):5572-82. PubMed ID: 16165256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.
    Oertli D; Marti WR; Zajac P; Noppen C; Kocher T; Padovan E; Adamina M; Schumacher R; Harder F; Heberer M; Spagnoli GC
    Hum Gene Ther; 2002 Mar; 13(4):569-75. PubMed ID: 11874634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
    Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P
    Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
    Chung SW; Cohen EP; Kim TS
    Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
    Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
    Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding murine MHC class II and costimulatory molecules.
    Marti WR; Oertli D; Meko JB; Norton JA; Tsung K
    J Immunol Methods; 1997 Jan; 200(1-2):191-8. PubMed ID: 9005958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
    Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
    Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.